SCHEMBL7587426

SCHEMBL7587426

CCCOC(=O)CN1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.46
KCNA3 P22001 1/20 0.46
USP14 P54578 1/20 0.43
DRD2 P14416 4/20 0.42
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
BTK Q06187 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
HSD11B1 P28845 2/20 0.40
CYP2C9 P11712 1/20 0.40
CCR5 P51681 1/20 0.39
EPHX1 P07099 2/20 0.39
DRD3 P35462 1/20 0.39
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840620 0.93 KCNA3 (0.44) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL7578299 0.90 CTSK (0.48) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL7586943 0.85 CTSK (0.51) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL18551142 0.83 KCNA3 (0.43) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL3448253 0.82 CTSK (0.52) CTSKKCNA3USP14DRD2BTK
SCHEMBL3448248 0.82 CTSK (0.52) CTSKKCNA3USP14DRD2BTK
SCHEMBL2693344 0.81 KCNA3 (0.54) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL12971748 0.81 KCNA3 (0.57) CTSKKCNA3DRD2CKS1BSKP1
SCHEMBL3965693 0.81 CTSK (0.55) CTSKKCNA3USP14DRD2CKS1B
SCHEMBL7587459 0.81 CTSK (0.47) CTSKKCNA3USP14DRD2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020082420-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-27 US disclosed
EP-1163242-A2 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM Boehringer Ingelheim Pharma KG (DE) 2001-12-19 EP disclosed
WO-2000055162-A2 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082420-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them PKD1, REN, CYP11B1 CTSK 2841/4885KCNA3 2714/4885USP14 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.